Onconova Therapeutics Presents At The American Society Of Clinical Oncology Annual Meeting

/in /by

Onconova Therapeutics Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa, was presented on Saturday, June 3, 2023, during the “Melanoma/Skin Cancers” session.

Read the June 5 press release

Onconova Therapeutics Announces First Participant In Investigator-Sponsored Phase 2 Trial

/in /by

Onconova Therapeutics announced that the first participant has been dosed in an investigator-sponsored Phase 2 trial of oral rigosertib plus the PD-1 inhibitor pembrolizumab in patients with metastatic melanoma who have progressed on prior PD-1/L1 inhibitor therapy.

Read the May 25 press release